IMAB - I-Mab

-

$undefined

N/A

(N/A)

I-Mab NasdaqGM:IMAB I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Location: 2440 Research Boulevard, Rockville, MD, 20850, United States | Website: https://www.i-mabbiopharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

71.71M

Cash

168.6M

Avg Qtr Burn

N/A

Short % of Float

0.29%

Insider Ownership

11.18%

Institutional Own.

29.54%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Eftansomatropin alfa (TJ101) Details
Pediatric growth hormone deficiency

BLA

Submission

Phase 3

Update

Lemzoparlimab combo w/ azacitidine Details
High risk myelodysplastic syndromes

Phase 3

Update

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

Efineptakin alfa (TJ107) Details
Lymphopenia, Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Glioblastoma

Phase 2

Update

Uliledlimab + pembrolizumab Details
Cancer, Non-small cell lung carcinoma

Phase 2

Initiation

Felzartamab Details
Primary Membranous Nephropathy

Phase 1/2

Update

Phase 1b

Data readout

MOR210 (TJ210) Details
Solid tumor/s, Cancer

Phase 1

Update

Phase 1

Update

Olamkicept (TJ301) Details
Ulcerative colitis, Autoimmune disease

Failed

Discontinued

Enoblituzumab (TJ271) + Pembrolizumab Details
Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued